Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)

    ... Protocol Chairs and/or Protocol Officer. Alemtuzumab or ATG within 2 weeks of enrollment ...

    Clinical Trial last updated 05/22/2017 - 11:00am.

  2. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... be given on study is fludarabine , melphalan, and alemtuzumab . These drugs are designed to stop the growth of cancer cells, ... mg/m2 by vein on Day -2. Other Name: Alkeran Drug: Alemtuzumab 50 mg by vein on Day -1. Other Names: ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  3. Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

    ... antibodies. The main transplant backbone will remain as alemtuzumab , low dose total body irradiation of 300 cGy, and sirolimus; the ... Intervention:  Drug: Alemtuzumab Immunosuppressant Drug: Sirolimus ...

    Clinical Trial last updated 04/28/2016 - 9:09am.

  4. Drugs

    ... Generic Name Brand Name alemtuzumab C ampath ...

    Page last updated 03/02/2016 - 9:11am.

  5. Myelodysplastic Syndromes and autoimmune disorders: Cause or consequence?

    ... (ImiDs), antithymocyte globulin (ATG), and alemtuzumab ) due to the autoimmune component. ...

    Research Review last updated 05/02/2016 - 9:18am.

  6. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... of the following: Cytotoxic chemotherapy , alemtuzumab , or an adequate course of 5- azacitidine or ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  7. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen. Planned post-transplant therapy, ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.

  8. Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

    ... Associated Drug(s):  Alemtuzumab Fludarabine ... Drug: Reduced-Intensity Conditioning Regimen Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug ...

    Clinical Trial last updated 05/03/2016 - 10:36am.

  9. Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT (RIC HSCT NMD)

    ... Associated Drug(s):  Alemtuzumab Fludarabine ...

    Clinical Trial last updated 06/13/2016 - 2:18pm.

  10. Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

    ... Associated Drug(s):  Alemtuzumab Antithymocyte Globulin ... Intervention:  Drug: Alemtuzumab Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from ...

    Clinical Trial last updated 04/25/2016 - 10:59am.